Shares of fertility services provider Gaudium IVF and Women Health made their stock market debut on 27 February 2026, listing at a modest premium compared with the issue price.
The company’s initial public offering combined a fresh equity issue with an offer for sale by the promoter, attracting investor participation amid growing interest in healthcare and specialised medical service providers.
Gaudium IVF and Women Health shares commenced trading at ₹83 per share on both the National Stock Exchange and the BSE, representing a gain of around 5% over the IPO issue price.
The listing marked the company’s entry into public markets following the completion of its ₹165 crore offering.
The public issue consisted of a fresh issue of shares worth ₹90 crore alongside an offer for sale aggregating ₹75 crore by promoter Dr Manika Khanna. The IPO aimed to raise capital to support expansion initiatives while also providing partial liquidity to existing shareholders.
The offering received an overall subscription of 7.27 times, with bids placed for more than 10.63 crore equity shares against approximately 1.46 crore shares available for subscription, according to exchange data.
Funds raised through the fresh issue are planned to be deployed towards setting up 19 new in vitro fertilisation (IVF) centres across India. A portion of the proceeds will also be used for repayment of certain borrowings, with the remaining amount allocated for general corporate purposes.
Ahead of the public issue, the company raised ₹49.5 crore through an anchor investor round.
Institutional participants included MERU Investment Fund PCC-CELL, Carnelian India Multi Strategy Fund, Sanshi Fund I and Hornbill Orchid India Fund.
A total of 62,65,860 shares were allotted to anchor investors at ₹79 per share.
Founded by Dr Manika Khanna, Gaudium IVF and Women Health provides fertility treatment services across India. The company operates using a hub-and-spoke model, comprising seven primary hubs supported by 28 spoke centres spread across multiple states.
For the financial year 2024–25, the company reported revenue from operations of ₹70.72 crore and a profit after tax of ₹19.13 crore. In comparison, revenue stood at ₹47.89 crore and net profit at ₹10.31 crore in the previous financial year, indicating growth in operational scale.
Read More: Jaiprakash Associates Shares Rise 2% as CoC Approves Key Resolutions During CIRP Process.
The listing of Gaudium IVF and Women Health reflects investor interest in specialised healthcare businesses entering public markets. Market participants may continue to track the company’s expansion plans and financial performance as it deploys IPO proceeds and scales its treatment network.
Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.
Investments in the securities market are subject to market risks. Read all related documents carefully before investing.
Published on: Feb 27, 2026, 11:46 AM IST
Neha Dubey
Neha Dubey is a Content Analyst with 3 years of experience in financial journalism, having written for a leading newswire agency and multiple newspapers. At Angel One, she creates daily content on finance and the economy. Neha holds a degree in Economics and a Master’s in Journalism.
Know MoreWe're Live on WhatsApp! Join our channel for market insights & updates
Get the link to download the App
